These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24453783)

  • 1. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
    Fox RJ; Salter AR; Tyry T; Sun J; You X; Laforet G; Campagnolo D
    Int J MS Care; 2013; 15(4):194-201. PubMed ID: 24453783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
    Halpern R; Agarwal S; Dembek C; Borton L; Lopez-Bresnahan M
    Patient Prefer Adherence; 2011 Jan; 5():73-84. PubMed ID: 21423591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
    BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
    Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.
    Stewart TM; Tran ZV
    Int J MS Care; 2012; 14(1):46-53. PubMed ID: 24453732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.
    Correia I; Marques IB; Sousa M; Batista S; Ferreira R; Nunes C; Macário C; Cunha L; Sousa L
    J Clin Neurosci; 2016 Nov; 33():73-78. PubMed ID: 27542939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
    Degli Esposti L; Piccinni C; Sangiorgi D; Perrone V; Aledda L; Marrosu MG; Lombardo F
    Neurol Sci; 2017 Apr; 38(4):589-594. PubMed ID: 28078563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment satisfaction in multiple sclerosis.
    Glanz BI; Musallam A; Rintell DJ; Chitnis T; Weiner HL; Healy BC
    Int J MS Care; 2014; 16(2):68-75. PubMed ID: 25061430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
    Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive cost-effectiveness analysis of treatments for multiple sclerosis.
    Newton AN; Stica CM
    Int J MS Care; 2011; 13(3):128-35. PubMed ID: 24453716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.